Zobrazeno 1 - 10
of 408
pro vyhledávání: '"59"'
Publikováno v:
International Journal of Cancer. 97:796-803
The serologic response against virus-like particles (VLP) from 7 high risk genital papillomaviruses was investigated by ELISA in 147 Colombian women with invasive cervical cancer and 147 age-matched cytologically normal and HPV-DNA negative women. An
Autor:
Jéssica Rodrigues, Fernando M. L. Tavares, Sara Petronilho, Hugo Sousa, Inês Baldaque, Rui Henrique, Sofia Salta, Renata Cardoso Vieira, Helena Estevão-Pereira, Paula Monteiro, Carmen Jerónimo, Leonardo Maia-Moço, Ana E. Sousa, José Pedro Sequeira, Carla Bartosch
Publikováno v:
International Journal of Cancer. 149:1916-1925
Cervical cancer remains a health concern. Effective screening programs are critical to reduce the incidence and mortality. High-risk HPV (hr-HPV) testing as primary screening tool discloses high sensitivity but suboptimal specificity. Adequate triage
Autor:
Karolina A. Plonowska-Hirschfeld, Patrick K. Ha, Ramez Philips, Aru Panwar, Russell B. Smith, Andrew Coughlin, Jeremy D. Richmon, Edgar Ochoa, Farhoud Faraji, Matthew E. Herberg, Jeffrey J. Houlton, Charles S. Coffey, William R. Ryan, Bridget V. MacDonald, Arnaud F. Bewley, Theodore A Gobillot, Trevor Hackman, Aaron L. Zebolsky, Jonathan Mallen-St. Clair, Mary Jue Xu, Carole Fakhry, Joseph Curry, Arjun S. Joshi, Andrew J Holcomb, David Cognetti
Publikováno v:
Cancer. 127:3092-3106
Background The oncologic outcomes of surgery alone for patients with American Joint Committee on Cancer 7th edition (AJCC 7th) pN2a and pN2b human papillomavirus-associated oropharynx squamous cell carcinoma (HPV+OPSCC) are not clear. Methods The aut
Autor:
Hyo S. Han, Bruce A. Bach, Shannon Puhalla, David Maag, Hans Wildiers, Véronique Diéras, Dai Feng, Jean-Pierre M. Ayoub, Christine K. Ratajczak, Michael Friedlander, Bella Kaufman, Banu Arun
Publikováno v:
Cancer Research. 81:PS11-03
Background: Veliparib (Vel) is a potent PARP1/2 inhibitor with demonstrated antitumor activity when administered alone or combined with carboplatin and paclitaxel (C/P). The phase 3 randomized, double-blind, multicenter BROCADE3 study (NCT02163694) e
Publikováno v:
Ruiz de Azua Unzurrunzaga, G, Brewster, D H, Wild, S & Sivalingam, V N 2019, ' Declining Hysterectomy Prevalence and the Estimated Impact on Uterine Cancer Incidence in Scotland ', Cancer Epidemiology, vol. 59, pp. 227-231 . https://doi.org/10.1016/j.canep.2019.02.008
Ruiz de Azua Unzurrunzaga, G, Brewster, D H, Wild, S H & Sivalingam, V N 2019, ' Declining hysterectomy prevalence and the estimated impact on uterine cancer incidence in Scotland ', Cancer Epidemiology, vol. 59, pp. 227-231 . https://doi.org/10.1016/j.canep.2019.02.008
Ruiz de Azua Unzurrunzaga, G, Brewster, D H, Wild, S H & Sivalingam, V N 2019, ' Declining hysterectomy prevalence and the estimated impact on uterine cancer incidence in Scotland ', Cancer Epidemiology, vol. 59, pp. 227-231 . https://doi.org/10.1016/j.canep.2019.02.008
AIM: The prevalence of hysterectomy is decreasing worldwide. It is not clear whether changes in the population at risk (women with intact uteruses) have contributed to an increased uterine cancer incidence. This study aims to assess the effect of cha
Autor:
S Waters, Neville Davidson, David Houghton, Farah Rehman, Peter Harper, N.M.L. Battisti, Rebecca Roylance, A Denton, Ailsa Sita-Lumsden, S.R.D. Johnston, Belinda Kingston, Hartmut Kristeleit, A Ring, Sacha J Howell, J Choy, Chara Stavraka, Kabir Mohammed, R Fharat, Joshua King, Elinor J. Sawyer
Publikováno v:
Cancer Research. 79:P6-18
Background Palbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Program (CAP) previously allowed patients to receive it in 4th line. However, Palbociclib has not bee
Publikováno v:
Cancer Medicine
We examined the risk of prostate cancer in the Korean population stratified on the basis of age group and risk based on metabolic diseases, using National Health Insurance System (NHIS) data. Of the 51,827,813 people from the NHIS data in 2015, 10,87
Autor:
Howard D. Strickler, Meredith S. Shiels, Philip E. Castle, Eric A. Engels, Mark Machin, Ruth M. Pfeiffer, Ana P. Ortiz, Vivian Colón-López
Publikováno v:
Journal of Clinical Oncology. 36:68-75
Purpose People with HIV infection have an elevated risk of anal cancer. However, recent calendar trends are incompletely described, and which population subgroups might benefit from cancer screening is unknown. Methods We used linked data from HIV an
Autor:
Amaris Geisler, Dulce M. Barrios, Mario E. Lacouture, Rosa Nouvini, Sarah J. Noor, Gregory S. Phillips
Publikováno v:
Journal of Clinical Oncology. 39:2632-2632
2632 Background: Immune-related cutaneous adverse events (irCAEs) are the most common and often the first toxicity of immune checkpoint inhibitors (CPIs). In the general population, irCAEs occur on average within 3.6 weeks of treatment initiation and
Autor:
Bjørn Tore Gjertsen, Geir Bredholt, Stein-Erik Gullaksen, Øystein Bruserud, Tara Helen Dowling Dowling Steinsland, Emmet McCormack, Mihaela Popa, Calum Leitch, Jostein Dahle, Mireia Mayoral Safont, Helen Heyerdahl, Astri Maaland
Publikováno v:
Blood. 136:26-26
Acute myeloid leukaemia is a disease of the haematopoietic stem and progenitor cells distinguished by an impairment of proliferation, propagation and differentiation of the haematopoietic lineage[1]. AML is a heterogenous disease, where patient strat